|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's Range||108.8800 - 109.3800|
|52 Week Range||83.4500 - 109.3800|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.60%|
Small-cap stocks and related small-cap ETFs are on a torrid pace this year, but investors looking for even more exciting gains with ETFs tracking small companies may want to consider the iShares Micro-Cap ...
Smaller stocks and corresponding exchange traded funds have recently been enjoying renewed fanfare and rightfully so. Year-to-date, the iShares Russell 2000 ETF (NYSE: IWM) is up 9.6 percent, or double the gains of the large-cap S&P 500. Smaller small-caps, or micro-caps, are performing even better.
Shares of microcap stocks have surged to record highs, far outpacing the broader market, and that may be a bearish signal. According to Maley, since 2007 there have been six previous instances when the iShares Microcap ETF ( IWC) outperformed the S&P 500 Index (SPX) over the course of several months. The iShares Microcap ETF had an all-time record high close on June 6, up 12% year-to-date.
The Nasdaq Composite, on the other hand, reached its upside objective of 7600 in January and has been consolidating below that level ever since. Was that the move, and now we reverse from this key extension target? Or should we instead focus on the fact that the Nasdaq just went out at an all-time monthly closing high, which is a characteristic of an uptrend, not a downtrend?
As the greenback soars to its highest levels of the year, one trader sees a couple of market areas that could ride the currency's coattails. "I will caution one thing" on the IWM, said Cappelleri. The U.S. dollar index has not traded above 94 since December 2017.
Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by targeting peripheral kappa opioid receptors in affected patients. The company is developing a novel class of product candidates that target the body’s peripheral nervous system and certain immune cells. Of the seven analysts covering Cara Therapeutics in January 2018, six analysts gave the stock a “buy” or higher rating, and one recommended “hold.” The stock has a mean rating of 1.9 and a target price of $24.29.
On August 10, 2017, all of the sell-side analysts tracking Flotek Industries rated it as a “buy.” None of the analysts rated Flotek as a “hold” or “sell.”
Flotek Industries’ (FTK) cash from operating activities (or CFO) remained negative in 2Q17, continuing with a negative cash flow trend in 1Q17.
From 2Q16 to 2Q17, Flotek Industries’ (FTK) EBITDA margin (or EBITDA as a percentage of revenues) improved to 2.3% from 0.7%.
Flotek's (FTK) CFO (cash from operating activities) was negative in 1Q17, after being positive for three quarters. FTK’s CFO was -$2.5 million in 1Q17.
From 1Q16 to 1Q17, Flotek’s EBITDA margin shrank to 3.3% from 4.1%. FTK’s EBITDA margin has been 1.7%, on average, for the past five quarters.